Figure 6
The PAR1-PR enhances tumour growth more potently than PAR4-PR. The MDA-MB-231 breast cancer cells in Matrigel (106 cells in 250 μl, containing 10% PAR1-PR or PAR4-PR) were subcutaneously implanted in female nude mice. After 4 weeks, tumours were removed, weighted, and photographed. A portion of each tumour plug was used for measurement of haemoglobin content. (A) Five pairs of symmetrically implanted tumour plugs with PAR1-PR or PAR4-PR are shown. (B) Tumour growth ratios were calculated using the following formula: tumour growth ratio=(tumour weight with PAR1-PR (or PAR4-PR))/tumour weight with PAR1-PR. Mean±s.e.m. from five tumour pairs are plotted. *P<0.05 vs PAR1-PR. (C) Mean±s.e.m. of angiogenesis index of five tumour pairs are plotted. *P<0.05 vs PAR1-PR. A full colour version of this figure is available at the British Journal of Cancer journal online.
